Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1D; MOG CAR-Treg which is in phase I clinical trial for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; Multi-Edit/Allo MOG CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and Antigen-specific T-regulatory cell (Tregs) which is in preclinical trial to treat T1D. The company also develops CD6/CTLA4 CAR-Treg which is in phase I clinical trial to treat stage 3 T1D; CD6/CTLA4 CAR-Treg which is in preclinical trial for the treatment of vitiligo, atopic derm, psoriasis, and alopecia areata; CD6/CTLA4 CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and PTG-OO7 + Rituximab which is in preclinical trial to treat presympt T1D. In addition, it is developing cell therapies involve the use of human cells to regenerate a patient's damaged tissues or organs. The company was founded in 2015 and is headquartered in Gdansk, Poland.
Часто задаваемые вопросы
В каком секторе работает PolTREG S.A. (PTG)?
PolTREG S.A. относится к сектору Здравоохранение.
Какова текущая цена акций PolTREG S.A. (PTG)?
По последним данным, цена акций PolTREG S.A. составляет 20,30 PLN, предыдущее закрытие — 20,50 PLN. За последнюю торговую сессию акции PolTREG S.A. снизились на -0,20 PLN, что соответствует падению на -0,98%.
Выплачивает ли PolTREG S.A. (PTG) дивиденды?
Нет, PolTREG S.A. не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у PolTREG S.A. (PTG)?
У компании PolTREG S.A. бета 0.819, что означает, что её волатильность примерно соответствует рыночной.
